As of December 22, 2021, the team of President Wang Yan of the Cardiovascular Hospital Affiliated to Xiamen University has completed the enrollment of Sirius AFR jointly developed by Xiaxin and Sirius Medtech. The patients have achieved good surgical results and have recovered and discharged. At present, the first patient has completed the one month follow-up after operation, the symptoms of heart failure have been significantly reduced, and the clinical effect is good, marking that the atrial shunt implantation system independently developed in China has officially entered the clinical research stage, bringing a new treatment option for some patients with end-stage heart failure.